Fig. 4

PBX3 promotes GBM mesenchymal transition, migration and invasion via activating MEK/ERK1/2 signaling pathway. a U87 and U251 cells stably expressing LV-PBX3 or LV-NC were treated with U0126 for 24 h and immunoblotting analysis of p-MEK, MEK, p-ERK1/2, ERK1/2, N-cadherin, ZEB1, Slug and CD44 were performed. b and c Quantification of wound-healing (b) and transwell (c) assays. **indicates a statistical significant difference (p < 0.01) between LV-NC + U0126 (−) group and LV-PBX3 + U0126 (−) group. $ indicates a statistical significant difference (p < 0.01) between LV-NC + U0126 (−) group and LV-NC + U0126 (+) group. # indicates a statistical significant difference (p < 0.01) between LV-NC + U0126 (+) group and LV-PBX3 + U0126 (+) group. d U87 and U251 cells stably expressing LV-siRNA-PBX3 or LV-siRNA-NC were treated with PMA for 24 h and immunoblotting analysis of p-MEK, MEK, p-ERK1/2, ERK1/2, N-cadherin, ZEB1, Slug and CD44 were performed. e and f Quantification of wound-healing (e) and transwell (f) assays. **indicates a statistical significant difference (p < 0.01) between LV-siRNA-NC + PMA (−) group and LV-siRNA-PBX3 + PMA (−) group. $ indicates a statistical significant difference (p < 0.01) between LV-siRNA-NC + PMA (−) group and LV-siRNA-NC + PMA (+) group. # indicates a statistical significant difference (p < 0.01) between LV-siRNA-NC + PMA (+) group and LV-siRNA-PBX3 + PMA (+) group